Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1990 Dec;34(12):2407–2414. doi: 10.1128/aac.34.12.2407

Pharmacokinetics and serum bactericidal activities of quinolones in combination with clindamycin, metronidazole, and ornidazole.

M Boeckh 1, H Lode 1, K M Deppermann 1, S Grineisen 1, F Shokry 1, R Held 1, K Wernicke 1, P Koeppe 1, J Wagner 1, C Krasemann 1, et al.
PMCID: PMC172070  PMID: 2088195

Abstract

To enhance the antimicrobial spectrum of the quinolones against anaerobic organisms and gram-positive bacteria, we investigated in two studies the parenteral combinations of ciprofloxacin (200 mg) and ofloxacin (200 mg) with metronidazole (500 mg) or clindamycin (600 mg) and the oral combinations of enoxacin (400 mg) and fleroxacin (400 mg) with metronidazole (400 mg), clindamycin (300 mg), or ornidazole (500 mg) (only with fleroxacin). The pharmacokinetics and serum bactericidal activities (SBAs) against 5 aerobic and 2 anaerobic species (total, 58 strains) were determined in two groups of 10 healthy volunteers by using a randomized crossover study design. The additions of metronidazole, clindamycin, and ornidazole did not affect the pharmacokinetics of the quinolones. The combination of clindamycin with ciprofloxacin, ofloxacin, and, to a lesser extent, fleroxacin resulted in an increase of the SBA against gram-positive strains (mean peak titers): Staphylococcus aureus, ciprofloxacin alone, 1:5.5; ciprofloxacin-clindamycin, 1:19.9; ofloxacin alone, 1:3.6; ofloxacin-clindamycin, 1:17.5; fleroxacin alone, 1:4.3; fleroxacin-clindamycin, 1:8.1; Streptococcus pneumoniae (fleroxacin and enoxacin were not tested), ciprofloxacin alone, 1:2.0; ciprofloxacin-clindamycin, 1:53; ofloxacin alone, 1:2.6; and ofloxacin-clindamycin, 1:49.2. The high SBA of quinolones against gram-negative bacteria was not affected by the combinations; however, relatively low activities against Pseudomonas aeruginosa were detected. In general, against anaerobic bacteria, low bactericidal activities were determined in both studies (mean peak titers ranged from 1:2.1 to 1:3.1; mean trough titers range from 1:2.0 to 1:2.9). In clinical settings with severe mixed infections, a parenteral therapy consisting of modern quinolones together with clindamycin or imidazole derivatives seems to be active and offers no obvious interactions.

Full text

PDF
2408

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bellido F., Pechère J. C. Laboratory survey of fluoroquinolone activity. Rev Infect Dis. 1989 Jul-Aug;11 (Suppl 5):S917–S924. doi: 10.1093/clinids/11.supplement_5.s917. [DOI] [PubMed] [Google Scholar]
  2. Benet L. Z. Effect of route of administration and distribution on drug action. J Pharmacokinet Biopharm. 1978 Dec;6(6):559–585. doi: 10.1007/BF01062110. [DOI] [PubMed] [Google Scholar]
  3. Boeckh M., Lode H., Borner K., Höffken G., Wagner J., Koeppe P. Pharmacokinetics and serum bactericidal activity of vancomycin alone and in combination with ceftazidime in healthy volunteers. Antimicrob Agents Chemother. 1988 Jan;32(1):92–95. doi: 10.1128/aac.32.1.92. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Borner K., Höffken G., Lode H., Koeppe P., Prinzing C., Glatzel P., Wiley R., Olschewski P., Sievers B., Reinitz D. Pharmacokinetics of ciprofloxacin in healthy volunteers after oral and intravenous administration. Eur J Clin Microbiol. 1986 Apr;5(2):179–186. doi: 10.1007/BF02013983. [DOI] [PubMed] [Google Scholar]
  5. Borner K., Lode H., Höffken G., Prinzing C., Glatzel P., Wiley R. Liquid chromatographic determination of ciprofloxacin and some metabolites in human body fluids. J Clin Chem Clin Biochem. 1986 May;24(5):325–331. doi: 10.1515/cclm.1986.24.5.325. [DOI] [PubMed] [Google Scholar]
  6. Bremner D. A., Dickie A. S., Singh K. P. In-vitro activity of fleroxacin compared with three other quinolones. J Antimicrob Chemother. 1988 Oct;22 (Suppl 500):19–23. doi: 10.1093/jac/22.supplement_d.19. [DOI] [PubMed] [Google Scholar]
  7. Chang T., Black A., Dunky A., Wolf R., Sedman A., Latts J., Welling P. G. Pharmacokinetics of intravenous and oral enoxacin in healthy volunteers. J Antimicrob Chemother. 1988 Feb;21 (Suppl B):49–56. doi: 10.1093/jac/21.suppl_b.49. [DOI] [PubMed] [Google Scholar]
  8. Cruciani M., Navarra A., Bono L., Concia E. Serum bactericidal activity against aerobes and anaerobes of volunteers receiving cefoxitin or cefotetan. Chemioterapia. 1988 Aug;7(4):261–263. [PubMed] [Google Scholar]
  9. Cuchural G. J., Jr, Tally F. P., Jacobus N. V., Aldridge K., Cleary T., Finegold S. M., Hill G., Iannini P., O'Keefe J. P., Pierson C. Susceptibility of the Bacteroides fragilis group in the United States: analysis by site of isolation. Antimicrob Agents Chemother. 1988 May;32(5):717–722. doi: 10.1128/aac.32.5.717. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Drusano G. L., Plaisance K. I., Forrest A., Standiford H. C. Dose ranging study and constant infusion evaluation of ciprofloxacin. Antimicrob Agents Chemother. 1986 Sep;30(3):440–443. doi: 10.1128/aac.30.3.440. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Farinotti R., Trouvin J. H., Bocquet V., Vermerie N., Carbon C. Pharmacokinetics of ofloxacin after single and multiple intravenous infusions in healthy subjects. Antimicrob Agents Chemother. 1988 Oct;32(10):1590–1592. doi: 10.1128/aac.32.10.1590. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Finegold S. M., Wexler H. M. Therapeutic implications of bacteriologic findings in mixed aerobic-anaerobic infections. Antimicrob Agents Chemother. 1988 May;32(5):611–616. doi: 10.1128/aac.32.5.611. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Georgopoulos A., Breyer S., Georgopoulos M., Mailer H., Graninger W. In-vitro activity of fleroxacin. J Antimicrob Chemother. 1988 Oct;22 (Suppl 500):25–29. doi: 10.1093/jac/22.supplement_d.25. [DOI] [PubMed] [Google Scholar]
  14. Greenblatt D. J., Koch-Weser J. Clinical pharmacokinetics (second of two parts). N Engl J Med. 1975 Nov 6;293(19):964–970. doi: 10.1056/NEJM197511062931905. [DOI] [PubMed] [Google Scholar]
  15. Greenwood D., Pearson N., Baker P., O'Grady F. In vitro activity of cefotaxine. J Antimicrob Chemother. 1979 Sep;5(5):609–610. doi: 10.1093/jac/5.5.609. [DOI] [PubMed] [Google Scholar]
  16. Grüneberg R. N., Felmingham D., O'Hare M. D., Robbins M. J., Perry K., Wall R. A., Ridgway G. L. The comparative in-vitro activity of ofloxacin. J Antimicrob Chemother. 1988 Sep;22 (Suppl 100):9–19. doi: 10.1093/jac/22.supplement_c.9. [DOI] [PubMed] [Google Scholar]
  17. Guglielmo B. J., Rodondi L. C. Comparison of antibiotic activities by using serum bactericidal activity over time. Antimicrob Agents Chemother. 1988 Oct;32(10):1511–1514. doi: 10.1128/aac.32.10.1511. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Heizmann W. R., Schmid R., Heilmann F., Werner H. Association experiments with aerobic and anaerobic pathogens: a model of in-vitro susceptibility testing in mixed infections. Activity of enoxacin, clindamycin, and metronidazole. Infection. 1989 May-Jun;17(3):160–164. doi: 10.1007/BF01644018. [DOI] [PubMed] [Google Scholar]
  19. Hooper D. C., Wolfson J. S. Mode of action of the quinolone antimicrobial agents: review of recent information. Rev Infect Dis. 1989 Jul-Aug;11 (Suppl 5):S902–S911. doi: 10.1093/clinids/11.supplement_5.s902. [DOI] [PubMed] [Google Scholar]
  20. Höffken G., Lode H., Prinzing C., Borner K., Koeppe P. Pharmacokinetics of ciprofloxacin after oral and parenteral administration. Antimicrob Agents Chemother. 1985 Mar;27(3):375–379. doi: 10.1128/aac.27.3.375. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Koeppe P., Hamann C. A program for non-linear regression analysis to be used on desk-top computers. Comput Programs Biomed. 1980 Dec;12(2-3):121–128. doi: 10.1016/0010-468x(80)90058-6. [DOI] [PubMed] [Google Scholar]
  22. Leigh D. A. Antibacterial activity and pharmacokinetics of clindamycin. J Antimicrob Chemother. 1981 Jun;7 (Suppl A):3–9. doi: 10.1093/jac/7.suppl_a.3. [DOI] [PubMed] [Google Scholar]
  23. Lode H., Elvers A., Koeppe P., Borner K. Comparative pharmacokinetics of apalcillin and piperacillin. Antimicrob Agents Chemother. 1984 Jan;25(1):105–108. doi: 10.1128/aac.25.1.105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Lode H., Höffken G., Olschewski P., Sievers B., Kirch A., Borner K., Koeppe P. Pharmacokinetics of ofloxacin after parenteral and oral administration. Antimicrob Agents Chemother. 1987 Sep;31(9):1338–1342. doi: 10.1128/aac.31.9.1338. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Neu H. C. Synergy of fluoroquinolones with other antimicrobial agents. Rev Infect Dis. 1989 Jul-Aug;11 (Suppl 5):S1025–S1035. doi: 10.1093/clinids/11.supplement_5.s1025. [DOI] [PubMed] [Google Scholar]
  26. Nilsson-Ehle I., Ursing B., Nilsson-Ehle P. Liquid chromatographic assay for metronidazole and tinidazole: pharmacokinetic and metabolic studies in human subjects. Antimicrob Agents Chemother. 1981 May;19(5):754–760. doi: 10.1128/aac.19.5.754. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Panneton A. C., Bergeron M. G., LeBel M. Pharmacokinetics and tissue penetration of fleroxacin after single and multiple 400- and 800-mg-dosage regimens. Antimicrob Agents Chemother. 1988 Oct;32(10):1515–1520. doi: 10.1128/aac.32.10.1515. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Peck C. C., Sheiner L. B., Nichols A. I. The problem of choosing weights in nonlinear regression analysis of pharmacokinetic data. Drug Metab Rev. 1984;15(1-2):133–148. doi: 10.3109/03602538409015060. [DOI] [PubMed] [Google Scholar]
  29. Pohlod D. J., Saravolatz L. D., Somerville M. M. In-vitro susceptibility of staphylococci to fleroxacin in comparison with six other quinolones. J Antimicrob Chemother. 1988 Oct;22 (Suppl 500):35–41. doi: 10.1093/jac/22.supplement_d.35. [DOI] [PubMed] [Google Scholar]
  30. Reller L. B. Interaction of cefotaxime and desacetylcefotaxime against pathogenic bacteria. Assessment with the serum bactericidal test. Diagn Microbiol Infect Dis. 1984 Jun;2(3 Suppl):55S–61S. [PubMed] [Google Scholar]
  31. Reller L. B., Stratton C. W. Serum dilution test for bactericidal activity. II. Standardization and correlation with antimicrobial assays and susceptibility tests. J Infect Dis. 1977 Aug;136(2):196–204. doi: 10.1093/infdis/136.2.196. [DOI] [PubMed] [Google Scholar]
  32. Robinson A., Bartlett R. C., Mazens M. F. Antimicrobial synergy testing based on antibiotic levels, minimal bactericidal concentration, and serum bactericidal activity. Am J Clin Pathol. 1985 Sep;84(3):328–333. doi: 10.1093/ajcp/84.3.328. [DOI] [PubMed] [Google Scholar]
  33. Schwartz D. E., Jeunet F. Comparative pharmacokinetic studies of ornidazole and metronidazole in man. Chemotherapy. 1976;22(1):19–29. doi: 10.1159/000221906. [DOI] [PubMed] [Google Scholar]
  34. Sculier J. P., Klastersky J. Significance of serum bactericidal activity in gram-negative bacillary bacteremia in patients with and without granulocytopenia. Am J Med. 1984 Mar;76(3):429–435. doi: 10.1016/0002-9343(84)90662-4. [DOI] [PubMed] [Google Scholar]
  35. Townsend R. J., Baker R. P. Pharmacokinetic comparison of three clindamycin phosphate dosing schedules. Drug Intell Clin Pharm. 1987 Mar;21(3):279–281. doi: 10.1177/106002808702100310. [DOI] [PubMed] [Google Scholar]
  36. Van der Auwera P., Van Laethem Y., Defresne N., Husson M., Klastersky J. Comparative serum bactericidal activity against test anaerobes in volunteers receiving imipenem, clindamycin, latamoxef and metronidazole. J Antimicrob Chemother. 1987 Feb;19(2):205–210. doi: 10.1093/jac/19.2.205. [DOI] [PubMed] [Google Scholar]
  37. Watt B., Brown F. V. The in-vitro activity of ciprofloxacin in combination with other agents against anaerobes of clinical interest. J Antimicrob Chemother. 1986 May;17(5):679–680. doi: 10.1093/jac/17.5.679-a. [DOI] [PubMed] [Google Scholar]
  38. Weidekamm E., Portmann R., Partos C., Dell D. Single and multiple dose pharmacokinetics of fleroxacin. J Antimicrob Chemother. 1988 Oct;22 (Suppl 500):145–154. doi: 10.1093/jac/22.supplement_d.145. [DOI] [PubMed] [Google Scholar]
  39. Werk R., Schneider L. Ciprofloxacin in combination with metronidazole. Infection. 1988 Jul-Aug;16(4):257–260. doi: 10.1007/BF01650774. [DOI] [PubMed] [Google Scholar]
  40. Wolf R., Eberl R., Dunky A., Mertz N., Chang T., Goulet J. R., Latts J. The clinical pharmacokinetics and tolerance of enoxacin in healthy volunteers. J Antimicrob Chemother. 1984 Sep;14 (Suppl 100):63–69. doi: 10.1093/jac/14.suppl_c.63. [DOI] [PubMed] [Google Scholar]
  41. Wolfson J. S., Hooper D. C. The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro. Antimicrob Agents Chemother. 1985 Oct;28(4):581–586. doi: 10.1128/aac.28.4.581. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES